Search details
1.
Empagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 388(2): 117-127, 2023 01 12.
Article
in English
| MEDLINE | ID: mdl-36331190
2.
Chronic kidney disease, heart failure and neprilysin inhibition.
Nephrol Dial Transplant
; 35(4): 558-564, 2020 04 01.
Article
in English
| MEDLINE | ID: mdl-31028383
3.
Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.
Am J Kidney Dis
; 83(4): 427-428, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38260929
4.
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Kidney Int
; 103(4): 787-790, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36736537
5.
In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes.
Ann Intern Med
; 172(4): JC18, 2020 02 18.
Article
in English
| MEDLINE | ID: mdl-32066151
6.
In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.
Ann Intern Med
; 170(4): JC15, 2019 02 19.
Article
in English
| MEDLINE | ID: mdl-30776804
7.
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Hypertension
; 79(12): 2671-2681, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36082669
8.
Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report.
BMJ Open Qual
; 10(3)2021 07.
Article
in English
| MEDLINE | ID: mdl-34226245
Results
1 -
8
de 8
1
Next >
>>